LYMPHIT: an innovative easy-to-use and cost-efficient diagnostic microneedle patch for the early detection of Lymphedema

Projektinformationen

Lymphit

ID Finanzhilfevereinbarung: 836091

DOI

10.3030/836091

Projekt abgeschlossen

EK-Unterschriftsdatum 19 November 2018

Startdatum 1 Dezember 2018

Enddatum 31 März 2019

Finanziert unter

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

DICRONIS SAGL
Switzerland

Periodic Reporting for period 1 - Lymphit (LYMPHIT: an innovative easy-to-use and cost-efficient diagnostic microneedle patch for the early detection of Lymphedema)

Berichtszeitraum: 2018-12-01 bis 2019-03-31

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Lymphedema is a chronic condition which may be inherited (primary) or caused by injury to the lymphatic vessels (secondary). It is often-ignored and misunderstood condition but affects up to 250 million people throughout the world. Cancer survivors run a lifelong risk of secondary lymphedema, a disease with no known cure which is caused by damage to or removal of the lymph nodes because of surgery, chemotherapy and radiotherapy and characterized by swelling due to a marked accumulation of fluid in the limb. Although most cancer survivors developing secondary lymphoedema do so within the first three years following treatment, there is no standardized protocol for monitoring patients nor are there efficient, cost-effective methods for early detection of lymphedema. Diagnostic methods are highly inaccurate, can only detect the disease at an advanced and potentially irreversible stage, greatly decreasing patients’ quality-of-life and increasing healthcare costs. This project reviewed the technical and business feasibility of Lymphit. The first solution able to track the lymphatic activity and detect lymphedema at the earliest (sub-clinical) stage.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

Dicronis completed a full analysis of the technical and business potential of their Lymphit technology. The project allowed Dicronis to formalize a sound technical development plan that forms the foundation for Lymphit’s commercialization. The next critical step for commercialization is to complete a period of clinical studies. This includes a first in-human study that will validate Lymphit’s ability to measure lymphatic activity and prove its safety. Following the study’s successful conclusion, Dicronis will conduct a larger clinical study which will enable commercialization of Lymphit as a diagnostic tool for lymphedema. During the project, Dicronis spoke to commercialization partners and discussed distribution of Lymphit following the completion of the clinical trials. Dicronis developed a go-to-market strategy with a European focus and investigated their internationalisation to the US and Japan.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

Our innovative integrated system provides clinicians with a reliable, affordable diagnostic method to identify subclinical signs of lymphedema at least six months earlier than current diagnostic procedures. Lymphit reduces treatment costs by up to 50% by identifying the condition at a reversible stage. Medical practitioners can quickly and selectively prescribe conservative treatment, avoiding progression of the disease and enabling the patient to carry on everyday life as far as possible, thereby effecting a tenfold reduction in social costs associated with loss of productivity.

Company logo

Lymphedema external signs